Blood transfusion reduction with intravenous iron in gynaecological cancer patients receiving chemotherapy
Completed
- Conditions
- Chemotherapy-induced anaemiaCancerMalignant neoplasms of female genital organs
- Registration Number
- ISRCTN01957333
- Lead Sponsor
- Chulalongkorn University (Thailand)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 44
Inclusion Criteria
1. Female participants aged 20 - 65 years
2. Normal liver function
3. Normal kidney function
4. No prior radiotherapy or having received radiotherapy
5. At least one remaining cycle of chemotherapy
Exclusion Criteria
1. Iron hypersensitivity
2. Risk of iron overload such as chronic renal failure or thalassaemia major
3. Progressive disease
4. Bone marrow metastasis
5. Inability to monitor weekly complete blood counts
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of blood transfusion at the consecutive cycle of chemotherapy between oral and intravenous iron, measured at the time of next cycle of chemotherapy (3 - 4 weeks depending on the chemotherapy regimen).
- Secondary Outcome Measures
Name Time Method In both groups, assessed at the next cycle of chemotherapy (3 - 4 weeks depended on the chemotherapy regimen):<br>1. Haemoglobin and haematocrit increment<br>2. Number of blood transfusion units<br>3. Adverse events<br>4. Quality of life (QOL), also measured before treatment